Cargando…
Evolving role of cetuximab in the treatment of colorectal cancer
In recent years, the monoclonal epidermal growth factor receptor (EGFR)-targeting antibody cetuximab was introduced into systemic therapy of colorectal cancer and gained an established role in the treatment of this disease. Cetuximab was shown to be active as a single agent in chemorefractory metast...
Autores principales: | Schuch, Gunter, Kobold, Sebastian, Bokemeyer, Carsten |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3004666/ https://www.ncbi.nlm.nih.gov/pubmed/21188126 |
Ejemplares similares
-
Cetuximab in the management of colorectal cancer
por: Lenz, Heinz-Josef
Publicado: (2007) -
First-line targeted therapies in the treatment of metastatic colorectal cancer – role of cetuximab
por: Tonini, Giuseppe, et al.
Publicado: (2009) -
Prognostic and Diagnostic Value of Spontaneous Tumor-Related Antibodies
por: Kobold, Sebastian, et al.
Publicado: (2010) -
Optimising the use of cetuximab in the continuum of care for patients with metastatic colorectal cancer
por: Goldberg, Richard M, et al.
Publicado: (2018) -
Current status of treatment of metastatic colorectal cancer with special reference to cetuximab and elderly patients
por: Pfeiffer, Per, et al.
Publicado: (2009)